Comparing the Efficacy and Safety of KRAS G12C inhibitors for patients with NSCLC
Clinical trial efficacy and safety data between KRAS G12C inhibitors that inform initial treatment selection for patients with NSCLC.
EP: 1.An overview on KRAS+ mutated lung adenocarcinoma
EP: 2.Selecting Frontline Therapy for KRAS+ mutated lung adenocarcinoma
EP: 3.KRYSTAL-1: Review of Key Efficacy Data
EP: 4.Comparing the Efficacy and Safety of KRAS G12C inhibitors for patients with NSCLC
EP: 5.Strategies for monitoring and mitigating hepatotoxicity with KRAS G12C inhibitors
EP: 6.Key Considerations for Treating patients with NSCLC using KRAS inhibitors
Case: A 64-year-old male diagnosed with a KRAS G12C mutated stage IV adenocarcinoma
Clinical Presentation:
- A 64-year-old male presents with cough and fatigue
- PMH: hyperlipidemia (well controlled with simvastatin), GERD (takes Omeprazole)
- SH: married with 2 grown children who live in other states; 30 pack-year smoking history; no family history of cancer.
Initial Clinical Workup and Diagnosis:
- CT chest showed right upper lobe lung mass with contralateral lung nodules concerning metastases.
- PET/CT revealed additional metastases in the liver.
- Molecular Testing: KRAS G12C mutation
- Staging: IV adenocarcinoma; ECOG PS 1
Initial Treatments:
- Patient was initiated on carboplatin-pemetrexed + pembrolizumab.
- Good initial response after 4 cycles but progressed after 8 months.
Disease Progression and Subsequent Treatments:
- Experienced disease progression after 8 months of carboplatin-pemetrexed + pembrolizumab, notably growth in hepatic metastases
- Confirmed progression on CT and PET/CT scans
- After progression on initial chemo+IO, molecular testing confirmed retained KRAS G12C mutation.
- The patient then started on second-line therapy with the adagrasib.
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
